Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia

[1]  L. Gordon,et al.  Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially? , 2006, Bone Marrow Transplantation.

[2]  R. Obenchain,et al.  Allogeneic hematopoietic stem cell transplant (HSCT) in adults with acute myeloid leukemia (AML) – a single program experience , 2006 .

[3]  A. Advani,et al.  The role of post-remission chemotherapy for older patients with acute myelogenous leukemia , 2006, Leukemia & lymphoma.

[4]  J. Byrd,et al.  High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  J. Rossi,et al.  Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Naoe,et al.  Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission , 2005, Cancer.

[7]  J. Byrd,et al.  High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia , 2005, Bone Marrow Transplantation.

[8]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[9]  L. Rybicki,et al.  A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation , 2004, Bone Marrow Transplantation.

[10]  J. Bourhis,et al.  Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. , 2003, Blood.

[11]  W. Hiddemann,et al.  Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Stone,et al.  Older adults with acute myeloid leukemia , 2002, Current oncology reports.

[13]  T. Panzarella,et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. , 2002, Blood.

[14]  D. Horsman,et al.  Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[16]  L. Rybicki,et al.  Autologous hematopoietic cell transplantation for non-Hodgkin's lymphoma: 100 month follow-up , 2002, Bone Marrow Transplantation.

[17]  Ole Blaabjerg,et al.  Serum Lactate Dehydrogenase Isoenzyme 1 and Prediction of Death in Patients with Metastatic Testicular Germ Cell Tumors , 2001, Clinical chemistry and laboratory medicine.

[18]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[19]  A. Baruchel,et al.  Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM) , 2000, Bone Marrow Transplantation.

[20]  N. Schmitz,et al.  Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). , 2000, Blood.

[21]  M. Goormastic,et al.  Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma , 2000, Bone Marrow Transplantation.

[22]  J. Sierra,et al.  Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia , 2000, The Lancet.

[23]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.

[24]  R. Herrmann,et al.  Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia , 1999, British journal of haematology.

[25]  F. Hirsch,et al.  Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression , 1999, British Journal of Cancer.

[26]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[27]  M. Labopin,et al.  Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). , 1997, Blood.

[28]  R Storb,et al.  Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. , 1997, Blood.

[29]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[30]  P. Wilkinson,et al.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Vekhoff,et al.  Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial , 1996 .

[32]  F. Ferrara,et al.  Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly , 1996, British journal of haematology.

[33]  J. Klein,et al.  Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. , 1995, Bone marrow transplantation.

[34]  C. Bloomfield,et al.  Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. , 1994, Cancer genetics and cytogenetics.

[35]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[36]  K. Sullivan,et al.  Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Rimm,et al.  Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. , 1992, Blood.

[38]  J. Biggs,et al.  Female marrow donors increase the risk of acute graft‐versus‐host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum , 1986, British journal of haematology.